Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
Home » Non-culture based testing guidelines from the CDC/NHSN
Effective January 1, 2020, new guidance has been provided for the use of non-culture based testing methodologies (NCT) as it relates to laboratory-confirmed bloodstream infections (LCBI). If blood is collected for culture within 2 days before, or 1 day after the NCT, disregard the result of the NCT and use ONLY the result of the culture to make an LCBI surveillance determination. If no blood is collected for culture within this time period, use the result of the NCT for LCBI surveillance determination.1
If blood cultures are collected…
Species identification in just hours: Data generated by T2Bacteria users demonstrate its ability to benefit patients in the emergency department by providing information that leads to more rapid time to delivery of effective therapy, de-escalation of unnecessary therapy, and helping avoid premature discharge and readmission to the emergency department.2
With T2Candida, multiple hospitals have shown that making targeted treatment decisions faster leads to improved outcomes, better stewardship, and reduces the cost of sepsis management. These institutions have independently reported significant reductions in length of stay and antifungal utilization, as well as substantial cost savings.3,4
“The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections.”5
……………………………………….
1. CDC/NHSN Patient Safety Component Manual, 2019.
2. Voigt, Christopher, et al. “The T2Bacteria assay Is a sensitive and rapid detector of bacteremia that can be initiated in the emergency department and has potential to favorably influence subsequent therapy.” The Journal of emergency medicine 58.5 (2020): 785-796.
3. Wilson, N.M. et. al. Poster Presentation IDWeek 2016.
4. Estrada, S. J. Slide Presentation ASM 2016.
5. United States CMS FY 2020 inpatient prospective payments system final rule
T2 Biosystems
101 Hartwell Avenue
Lexington, MA 02421
Phone: 781-457-1200
Fax: 781-357-3080
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2022 T2 Biosystems, Inc.
Please tell us where you are visiting from: United States | Outside the United States